Evaluation of the efficacy and safety of a combination drug containing ambroxol, guaifenesin, and levosalbutamol versus a fixed-dose combination of bromhexine/guaifenesin/salbutamol in the treatment of productive cough in adult patients with acute bronchitis
- 作者: Zaitsev A.1,2, Leshchenko I.3,4,5, Esaulova N.3,5, Viktorova I.6
-
隶属关系:
- Burdenko Main Military Clinical Hospita
- ROSBIOTECH
- Ural State Medical University
- Ural Research Institute of Phthisiopulmonology – branch of the National Medical Research Center for Phthisiopulmonology and Infectious Diseases
- LLC “Medical Association “New Hospital”
- Omsk State Medical University
- 期: 卷 95, 编号 3 (2023)
- 页面: 236-242
- 栏目: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/132911
- DOI: https://doi.org/10.26442/00403660.2023.03.202099
- ID: 132911
如何引用文章
全文:
详细
Aim. To evaluate the efficacy and safety of a combination drug containing ambroxol, guaifenesin, and levosalbutamol, oral solution, versus Ascoril Expectorant, syrup (combination of bromhexine, guaifenesin, and salbutamol) in the treatment of productive cough in adult patients with acute bronchitis.
Materials and methods. This open-label, randomized, phase III study included patients with acute bronchitis who had a productive cough with difficulty in sputum expectoration. 244 patients were randomized in a 1:1 ratio and received 10 mL of the study drug or reference drug 3 times daily for 2 weeks. After 7 and 14 days of treatment, the physician evaluated patient’s subjective complaints and the efficacy of therapy. The primary endpoint was the proportion of patients with high and very high efficacy.
Results. The primary endpoint was reached by 70 (0.5738) patients in the study drug group and 54 (0.4426) in the reference drug group (p=0.04). The intergroup difference was 0.1311 [95% confidence interval: 0.0057; 0.2566]. The lower limit of the 95% confidence interval was above zero, which confirms the superiority of therapy with the study drug over therapy with Ascoril Expectorant. The proportion of patients with a 1-point total score reduction and with complete resolution of all symptoms according to the Modified Cough Relief and Sputum Expectoration Questionnaire after 7 and 14 days was numerically higher in the study drug group versus the reference drug group. There were no statistically significant differences between the groups in the incidence of adverse events.
Conclusion. The efficacy of a new combination drug containing ambroxol, guaifenesin, and levosalbutamol in the treatment of productive cough in adult patients with acute bronchitis is superior to the efficacy of Ascoril Expectorant. The safety profiles of the study drug and the reference drug were comparable.
作者简介
Andrey Zaitsev
Burdenko Main Military Clinical Hospita; ROSBIOTECH
Email: a-zaicev@yandex.ru
ORCID iD: 0000-0002-0934-7313
д-р мед. наук, проф., зав. каф. пульмонологии (с курсом аллергологии)
俄罗斯联邦, Moscow; MoscowIgor Leshchenko
Ural State Medical University; Ural Research Institute of Phthisiopulmonology – branch of the National Medical Research Center for Phthisiopulmonology and Infectious Diseases; LLC “Medical Association “New Hospital”
编辑信件的主要联系方式.
Email: a-zaicev@yandex.ru
ORCID iD: 0000-0002-1620-7159
д-р мед. наук, проф. каф. фтизиатрии и пульмонологии, гл. науч. сотр., врач-пульмонолог
俄罗斯联邦, Yekaterinburg; Yekaterinburg; YekaterinburgNatalia Esaulova
Ural State Medical University; LLC “Medical Association “New Hospital”
Email: a-zaicev@yandex.ru
ORCID iD: 0000-0001-9565-3570
канд. мед. наук, доц. каф. фтизиатрии и пульмонологии, зав. пульмонологическим отд-нием
俄罗斯联邦, Yekaterinburg; YekaterinburgInna Viktorova
Omsk State Medical University
Email: a-zaicev@yandex.ru
ORCID iD: 0000-0001-8728-2722
д-р мед. наук, проф., зав. каф. поликлинической терапии и внутренних болезней, гл. внештат. специалист по терапии и общей врачебной практике
俄罗斯联邦, Omsk参考
- Зайцев А.А., Лещенко И.В. Острый бронхит. Методические рекомендации. М.: ГВКГ им. Н.Н. Бурденко, 2022. Режим доступа: https://cough-conf.ru/wp-content/uploads/ostryj-bronhit_2022.pdf. Ссылка активна на 25.01.2023 [Zaitsev AA, Leshchenko IV. Ostryi bronkhit. Metodicheskie rekomendatsii. Moscow: Burdenko MMCH, 2022. Available at: https://cough-conf.ru/wp-content/uploads/ostryj-bronhit_2022.pdf. Accessed: 25.01.2023 (in Russian)].
- Зайцев А.А., Оковитый С.В. Кашель: дифференциальный диагноз и рациональная фармакотерапия. Терапевтический архив. 2014;86(12):85-91 [Zaitsev AA, Okovityi SV. Cough: Differential diagnosis and rational pharmacotherapy. Terapevticheskii Arkhiv (Ter. Arkh.). 2014;86(12):85-91 (in Russian)]. doi: 10.17116/terarkh2014861285-91
- Зайцев А.А., Оковитый С.В., Крюков Е.В. Современные возможности мукоактивной терапии. Фарматека. 2015;14:81-4. Режим доступа: https://pharmateca.ru/ru/archive/article/31934. Ссылка активна на 25.01.2023 [Zaitsev AA, Okovityi SV, Kryukov EV. Modern potentials of mucoactive therapy. Pharmateka. 2015;14:81-4. Available at: https://pharmateca.ru/ru/archive/article/31934. Accessed: 25.01.2023 (in Russian)].
- Лиджиева А.А., Смолярчук Е.А. Левосальбутамол – новые возможности лечения бронхиальной астмы. Ведомости Научного центра экспертизы средств медицинского применения. 2015;2:25-8. Режим доступа: https://www.vedomostincesmp.ru/jour/article/view/36?locale=ru_RU. Ссылка активна на 25.01.2023 [Lidzhieva AA, Smolyarehuk EA. Levosalbutamol and new opportunities for the treatment of bronchial asthma (review of the related studies). The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2015;2:25-8. Available at: https://www.vedomostincesmp.ru/jour/article/view/36?locale=ru_RU. Accessed: 25.01.2023 (in Russian)].
- Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4(2):213-26. doi: 10.1002/sim.4780040211
- Нургожин Т.С., Гуляев А.Е., Ермекбаева Б.А., и др. Результаты международного многоцентрового неинтервенционного клинического исследования эффективности и безопасности аскорила экспекторанта при лечении кашля, проведенного в Республике Казахстан и в Республике Узбекистан. Клиническая фармакология. 2013;6:50-5. Режим доступа: http://www.medzdrav.kz/images/magazine/medecine/2013/2013-1/M_01-13_16-21.pdf. Ссылка активна на 25.01.2023 [Nurgozhin TS, Gulyayev AE, Yermekbayeva BA, et al. The results of the international multicenter non-interventional clinical research of the effectiveness and safety of askoril expectorant in treatment of cough in the Republic of Kazakhstan and in the Republci of Uzbekistan. Clinical Pharmacology. 2013;6:50-5. Available at: http://www.medzdrav.kz/images/magazine/medecine/2013/2013-1/M_01-13_16-21.pdf. Accessed: 25.01.2023 (in Russian)].
- Оковитый С.В., Анисимова Н.А. Фармакологические подходы к противокашлевой терапии. РМЖ. 2011;23:1450. Режим доступа: https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Farmakologicheskie_podhody_k_protivokashlevoy_terapii/ Ссылка активна на 25.01.2023 [Okovityi SV, Anisimiva NA. Pharmacological approaches to antitussive therapy. RMJ. 2011;23:1450. Available at: https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Farmakologicheskie_podhody_k_protivokashlevoy_terapii/ Accessed: 25.01.2023 (in Russian)].
- Клячкина И.Л. Муколитик амброксол в программе лечения заболеваний нижних дыхательных путей. Справочник поликлинического врача. 2010;10:15-9. Режим доступа: https://omnidoctor.ru/upload/iblock/5ab/5ab1177314ee568750560c9bd6acdd94.pdf. Ссылка активна на 25.01.2023 [Klyachkina IL. Mucolytic ambroxol in the treatment of lung diseases. Handbook for Practitioners Doctors. 2010;10:15-9. Available at: https://omnidoctor.ru/upload/iblock/5ab/5ab1177314ee568750560c9bd6acdd94.pdf. Accessed: 25.01.2023 (in Russian)].